Anti-CD20 therapy reduces microglial activation and lesion volume in focal models of pattern I and pattern II multiple sclerosis

被引：0
|
作者：
Anthony, D. C.
Campbell, S. J.
Seneca, N.
Balazs, M.
Leppert, D.
机构：
[1] Univ Oxford, Oxford, England
[2] Roche, Basel, Switzerland
[3] Genentech Inc, San Francisco, CA 94080 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P734
引用
收藏
页码：S325 / S326
页数：2
相关论文
共 50 条
  • [1] Anti-CD20 Therapy Reduces Microglial Activation and Lesion Volume in Focal Models of Pattern I and Pattern II Multiple Sclerosis
    Leppert, David
    Campbell, Sandra
    Seneca, Nicolas
    Warren, Edward
    Balazs, Mercedes
    Anthony, Daniel
    NEUROLOGY, 2012, 78
  • [2] Anti-CD20 therapy reduces microglial activation and lesion volume in focal models of pattern I and pattern II multiple sclerosis
    Anthony, Daniel
    Campbell, Sandra
    Dickens, Alex
    Checa, Begona
    Kersemans, Veerle
    Seneca, Nicholas
    Balazs, Mercedesz
    Leppert, David
    JOURNAL OF NEUROIMMUNOLOGY, 2012, 253 (1-2) : 139 - 140
  • [3] Anti-CD20 therapy down-regulates lesion formation and microglial activation in pattern I and pattern II rat models of multiple sclerosis
    Anthony, Daniel C.
    Dickens, Alex M.
    Seneca, Nicholas
    Couch, Yvonne
    Campbell, Sandra
    Checa, Begona
    Kersemans, Veerle
    Warren, Edward A.
    Tredwell, Matthew
    Sibson, Nicola R.
    Gouverneur, Veronique
    Leppert, David
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 275 (1-2) : 1 - 2
  • [4] Anti-CD20 therapy reduces lesion volume and activated microglia in rodent models of multiple sclerosis
    Seneca, Nicholas
    Campbell, Sandra J.
    Balazs, Mercedes
    Leppert, David
    Anthony, Daniel C.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2012, 32 : S58 - S59
  • [5] Development of anti-CD20 therapy for multiple sclerosis
    Bartok, Beatrix
    Silverman, Gregg J. J.
    EXPERIMENTAL CELL RESEARCH, 2011, 317 (09) : 1312 - 1318
  • [6] Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
    Heming, Michael
    Wiendl, Heinz
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (06)
  • [7] Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis
    Kim, John
    Kesselheim, Aaron S.
    Bove, Riley
    Avorn, Jerry
    Rome, Benjamin N.
    JAMA NEUROLOGY, 2024, 81 (01) : 85 - 87
  • [8] Anti-CD20 therapy for multiple sclerosis-associated uveitis: A case series
    Stascheit, Frauke
    Ruebsam, Anne
    Otto, Carolin
    Meisel, Andreas
    Ruprecht, Klemens
    Pleyer, Uwe
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (10) : 3028 - 3038
  • [9] Unraveling the T-B tangle in anti-CD20 multiple sclerosis therapy
    Waisman, Ari
    Ebering, Anna
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (51) : 25376 - 25377
  • [10] Comparison of MRI signatures in pattern I and II multiple sclerosis models
    Serres, Sebastien
    Anthony, Daniel C.
    Jiang, Yanyan
    Campbell, Sandra J.
    Broom, Kerry A.
    Khrapitchev, Alexandre
    Sibson, Nicola R.
    NMR IN BIOMEDICINE, 2009, 22 (10) : 1014 - 1024
12345